Insider Selling: Seattle Genetics, Inc. (SGEN) COO Sells 3,729 Shares of Stock
Seattle Genetics, Inc. (NASDAQ:SGEN) COO Eric Dobmeier sold 3,729 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $58.75, for a total value of $219,078.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Eric Dobmeier also recently made the following trade(s):
- On Wednesday, November 15th, Eric Dobmeier sold 9,600 shares of Seattle Genetics stock. The stock was sold at an average price of $57.80, for a total value of $554,880.00.
- On Friday, November 17th, Eric Dobmeier sold 35,000 shares of Seattle Genetics stock. The stock was sold at an average price of $58.25, for a total value of $2,038,750.00.
Shares of Seattle Genetics, Inc. (SGEN) traded up $0.70 during trading hours on Wednesday, hitting $56.75. The stock had a trading volume of 1,033,171 shares, compared to its average volume of 964,263. Seattle Genetics, Inc. has a 1 year low of $45.31 and a 1 year high of $71.32.
Several large investors have recently made changes to their positions in SGEN. Quantbot Technologies LP lifted its holdings in Seattle Genetics by 116.5% in the third quarter. Quantbot Technologies LP now owns 2,654 shares of the biotechnology company’s stock valued at $144,000 after acquiring an additional 1,428 shares during the period. First Manhattan Co. lifted its holdings in Seattle Genetics by 31.3% in the second quarter. First Manhattan Co. now owns 3,150 shares of the biotechnology company’s stock valued at $162,000 after acquiring an additional 750 shares during the period. Bristlecone Advisors LLC bought a new position in Seattle Genetics in the third quarter valued at about $180,000. Virtu Financial LLC bought a new position in Seattle Genetics in the third quarter valued at about $203,000. Finally, DRW Securities LLC bought a new position in Seattle Genetics in the second quarter valued at about $207,000. 98.96% of the stock is currently owned by hedge funds and other institutional investors.
SGEN has been the topic of several recent research reports. Barclays raised Seattle Genetics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $60.00 to $70.00 in a research note on Friday, October 20th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Seattle Genetics in a research note on Friday, October 27th. SunTrust Banks set a $52.00 price target on Seattle Genetics and gave the stock a “hold” rating in a research note on Friday, October 27th. Zacks Investment Research raised Seattle Genetics from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a research note on Tuesday, October 10th. Finally, J P Morgan Chase & Co increased their target price on Seattle Genetics from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, October 30th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $63.53.
ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/06/insider-selling-seattle-genetics-inc-sgen-coo-sells-3729-shares-of-stock.html.
Seattle Genetics Company Profile
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.